{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:31:13Z","timestamp":1788985873849,"version":"build-2803163510"},"reference-count":71,"publisher":"Tech Science Press","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJU"],"published-print":{"date-parts":[[2025]]},"DOI":"10.32604\/cju.2025.064912","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T04:58:22Z","timestamp":1747717102000},"page":"145-165","source":"Crossref","is-referenced-by-count":2,"title":["Botulinum toxin A in idiopathic overactive bladder: a narrative review of 5410 cases"],"prefix":"10.32604","volume":"32","author":[{"given":"Salim","family":"Lachkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Ibrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Boualaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hachem El","family":"Sayegh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yassine","family":"Nouini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"17807","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1002\/nau.20737","article-title":"Reviewing the ICS, 2002 terminology report: the ongoing debate","volume":"28","author":"Abrams","year":"2009","journal-title":"Neurourol Urodyn"},{"key":"ref2","first-page":"167","article-title":"Global prevalence of overactive bladder: a systematic review and meta-analysis","volume":"21","author":"Zhang","year":"2025 f\u00e9vr 14","journal-title":"Int Urogynecol J"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3122\/jabfm.2023.230471R1","article-title":"Non-surgical management of urinary incontinence","volume":"37","author":"Al-Dossari","year":"2024","journal-title":"J Am Board Fam Med"},{"key":"ref4","unstructured":"Food and Drug Administration. Highlights of prescribing information 2017 [cited 2025 Mar 8]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/103000s5302lbl.pdf."},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CU9.0000000000000124","article-title":"The role of botulinum toxin in the management of nonneurogenic overactive bladder in children: highlights for clinical practice. A systematic review","volume":"18","author":"C\u00e2ncio Martins Bissaia Barreto","year":"2024 mars","journal-title":"Curr Urol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.euf.2020.06.013","article-title":"Predictors of poor response and adverse events following botulinum toxin a for refractory idiopathic overactive bladder: a systematic review","volume":"7","author":"Abrar","year":"2021","journal-title":"Eur Urol Focus"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s00192-021-05040-1","article-title":"Outcome reporting in randomized controlled trials (RCTs) on the pharmacological management of idiopathic overactive bladder (OAB) in women; a systematic review for the development of core outcome sets (COS)","volume":"33","author":"Moussa","year":"2022 mai","journal-title":"Int Urogynecol J"},{"key":"ref8","first-page":"804","article-title":"Comparative efficacy and safety of mirabegron and vibegron in female patients with overactive bladder: a systematic review and meta-analysis of randomized controlled trials","volume":"111","author":"Liang","year":"2025 f\u00e9vr 17","journal-title":"Urology"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.juro.2008.03.028","article-title":"Refractory idiopathic urge urinary incontinence and botulinum a injection","volume":"180","author":"Brubaker","year":"2008 juill 1","journal-title":"J Urol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.urology.2007.11.039","article-title":"Urodynamic assessment of poor responders after botulinum toxin-a treatment for overactive bladder","volume":"71","author":"Sahai","year":"2008 mars 1","journal-title":"Urology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1016\/j.juro.2009.01.117","article-title":"Outcome of a randomized, double-blind, placebo controlled trial of botulinum a toxin for refractory overactive bladder","volume":"181","author":"Flynn","year":"2009 juin","journal-title":"J Urol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/nau.20611","article-title":"Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units","volume":"28","author":"Cohen","year":"2009 mars","journal-title":"Neurourol Urodyn"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","article-title":"Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial","volume":"184","author":"Dmochowski","year":"2010 d\u00e9c","journal-title":"J Urol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4103\/0974-7796.82170","article-title":"Prospective randomized trial of 100u vs 200u botox in the treatment of idiopathic overactive bladder","volume":"3","author":"AlTaweel","year":"2011","journal-title":"Urol Ann"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1111\/j.1742-1241.2011.02663.x","article-title":"The safety and efficacy of botulinum toxin-A in the management of bladder oversensitivity: a randomised double-blind placebo-controlled trial: botulinum toxin-A and bladder oversensitivity","volume":"65","author":"Dowson","year":"2011 juin","journal-title":"Int J Clin Pract"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/nau.21021","article-title":"Urodynamic results and clinical outcomes with intradetrusor injections of onabotulinumtoxina in a randomized, placebo-controlled dose-finding study in idiopathic overactive bladder","volume":"30","author":"Rovner","year":"2011 avr","journal-title":"Neurourol Urodyn"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.eururo.2011.10.028","article-title":"Efficacy and safety of low doses of onabotulinumtoxina for the treatment of refractory idiopathic overactive bladder: a multicentre, double-blind, randomised, placebo-controlled dose-ranging study","volume":"61","author":"Denys","year":"2012 mars","journal-title":"European Urol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2012.03.005","article-title":"OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial","volume":"62","author":"Fowler","year":"2012 juill","journal-title":"Eur Urol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.eururo.2011.12.056","article-title":"Botulinum toxin A versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX Study)","volume":"62","author":"Tincello","year":"2012 sept","journal-title":"European Urol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","article-title":"OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial","volume":"189","author":"Nitti","year":"2013 juin","journal-title":"J Urol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial","volume":"64","author":"Chapple","year":"2013 ao\u00fbt","journal-title":"European Urol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/iju.14176","article-title":"OnabotulinumtoxinA (botulinum toxin type A) for the treatment of Japanese patients with overactive bladder and urinary incontinence: results of single-dose treatment from a phase III, randomized, double-blind, placebo-controlled trial (interim analysis)","volume":"27","author":"Yokoyama","year":"2020 Mars","journal-title":"Int J of Urology"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0022-5347(06)00590-8","article-title":"Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics","volume":"176","author":"Schmid","year":"2006 juill","journal-title":"J Urol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1111\/j.1464-410X.2009.08402.x","article-title":"Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial","volume":"103","author":"Sahai","year":"2009 Juin","journal-title":"BJU Int"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.eururo.2010.09.007","article-title":"Adverse events of intravesical botulinum toxin A injections for idiopathic detrusor overactivity: risk factors and influence on treatment outcome","volume":"58","author":"Kuo","year":"2010 d\u00e9c 1","journal-title":"Eur Urol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.juro.2012.11.089","article-title":"Increased risk of large post-void residual urine and decreased long-term success rate after intravesical onabotulinumtoxinA injection for refractory idiopathic detrusor overactivity","volume":"1189","author":"Liao","year":"2013 mai 1","journal-title":"J Urol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1002\/nau.22494","article-title":"Diabetes mellitus does not affect the efficacy and safety of intravesical onabotulinumtoxina injection in patients with refractory detrusor overactivity","volume":"33","author":"Wang","year":"2014 oct","journal-title":"Neurourol Urodyn"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/nau.22642","article-title":"Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome","volume":"34","author":"Osborn","year":"2015 sept","journal-title":"Neurourol Urodyn"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"e0147137","DOI":"10.1371\/journal.pone.0147137","article-title":"Factors associated with therapeutic efficacy of intravesical onabotulinumtoxinA injection for overactive bladder syndrome. Hills RK, \u00e9diteur","volume":"11","author":"Hsiao","year":"2016 janv 29","journal-title":"PLoS One"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/nau.22948","article-title":"Patient factors associated with onabotulinum toxin A treatment outcome in women with detrusor overactivity","volume":"36","author":"Owen","year":"2017 f\u00e9vr","journal-title":"Neurourol Urodyn"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s00192-016-3212-4","article-title":"Urinary retention in female OAB after intravesical Botox injection: who is really at risk?","volume":"28","author":"Miotla","year":"2017 juin","journal-title":"Int Urogynecol J"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.juro.2017.04.103","article-title":"Characteristics associated with treatment response and satisfaction in women undergoing onabotulinumtoxinA and sacral neuromodulation for refractory urgency urinary incontinence","volume":"198","author":"Richter","year":"2017 oct","journal-title":"J Urol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1080\/03007995.2018.1443061","article-title":"Clean intermittent catheterization rates after initial and subsequent treatments with onabotulinumtoxinA for non-neurogenic overactive bladder in real-world clinical settings","volume":"34","author":"Kennelly","year":"2018 oct 3","journal-title":"Curr Med Res Opin"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/SPV.0000000000000496","article-title":"Real-world retention rates after intravesical onabotulinumtoxinA for idiopathic overactive bladder","volume":"24","author":"Liberman","year":"2018 nov","journal-title":"Female Pelvic Med Reconstr Surg"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.urology.2018.09.016","article-title":"Onabotulinum toxin A injections in men with refractory idiopathic detrusor overactivity","volume":"123","author":"Faure Walker","year":"2019 janv","journal-title":"Urol Janv"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.urology.2019.08.054","article-title":"Predictors of poor response and adverse events following botulinum Toxin-A for refractory idiopathic overactive bladder","volume":"135","author":"Abrar","year":"2020 janv","journal-title":"Urology"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/JU.0000000000000525","article-title":"Treatment response and complications after intradetrusor onabotulinumtoxinA injection in male patients with idiopathic overactive bladder syndrome","volume":"203","author":"Mateu Arrom","year":"2020 f\u00e9vr","journal-title":"J Urol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00192-024-05960-8","article-title":"Predictive factors for clean intermittent catheterization after intravesical onabotulinumtoxinA injections in women with overactive bladder: a danish retrospective cohort study","volume":"36","author":"El Issaoui","year":"2025 janv","journal-title":"Int Urogynecol J"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00192-025-06047-8","article-title":"Efficacy of 100-U Onabotulinumtoxin A treatment in female idiopathic overactive bladder\u2014a prospective follow-up study","volume":"36","author":"Nurkkala","year":"2025 janv 31","journal-title":"Int Urogynecol J"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.urology.2006.05.044","article-title":"Assessment of treatment outcomes in patients with overactive bladder: importance of objective and subjective measures","volume":"68","author":"Abrams","year":"2006 ao\u00fbt","journal-title":"Urology"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. In: Cochrane database of systematic reviews. Chichester, UK: John Wiley & Sons, Ltd., 2011 [cit\u00e9 2025 f\u00e9vr 26]. p. CD005493.pub3. doi:10.1002\/14651858.CD005493.pub3.","DOI":"10.1002\/14651858.CD005493.pub3"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.eururo.2011.07.001","article-title":"Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA)","volume":"60","author":"Mangera","year":"2011 oct","journal-title":"Eur Urol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jgyn.2014.06.011","article-title":"Intra-detrusor injection of botulinum toxin for female refractory idiopathic overactive bladder syndrome","volume":"43","author":"Deffieux","year":"2014 oct","journal-title":"J Gynecol Obstet Biol Reprod"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.purol.2015.01.006","article-title":"Idiopathic overactive bladder and BOTOX(\u00ae): literature review","volume":"25","author":"Gam\u00e9","year":"2015 juin","journal-title":"Prog Urol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.JAA.0000476217.57808.c4","article-title":"Botulinum toxin as a treatment for refractory overactive bladder","volume":"29","author":"Harris","year":"2016 f\u00e9vr","journal-title":"JAAPA"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1002\/nau.21150","article-title":"Botulinum toxin outcomes for idiopathic overactive bladder stratified by indication: lack of anticholinergic efficacy versus intolerability","volume":"30","author":"Makovey","year":"2011 nov","journal-title":"Neurourol Urodyn"},{"key":"ref47","first-page":"S46\u2013S55","article-title":"How can we better manage drug-resistant OAB\/DO? ICI-RS 2018","volume":"38 Suppl 5","author":"Chermansky","year":"2019 d\u00e9c","journal-title":"Neurourol Urodyn"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00345-016-1862-y","article-title":"Long-term follow-up of intravesical botulinum toxin\u2014a injections in women with idiopathic overactive bladder symptoms","volume":"35","author":"Marcelissen","year":"2017 F\u00e9vr","journal-title":"World J Urol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejogrb.2023.11.010","article-title":"Measures of quality of life of people with neurogenic overactive bladder: a systematic review of psychometric properties","volume":"292","author":"Usman Ali","year":"2024 Janv","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.urology.2005.12.006","article-title":"Minimal clinically important differences in incontinence quality-of-life scores in stress urinary incontinence","volume":"67","author":"Yalcin","year":"2006 Juin","journal-title":"Urology"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.spinee.2007.01.008","article-title":"Understanding the minimum clinically important difference: a review of concepts and methods","volume":"7","author":"Copay","year":"2007","journal-title":"Spine J"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"e28032","DOI":"10.2196\/28032","article-title":"Developing core outcome sets (COS) and core outcome measures sets (COMS) in cosmetic gynecological interventions: protocol for a development and usability study","volume":"10","author":"Doumouchtsis","year":"2021 nov 15","journal-title":"JMIR Res Protoc"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.eururo.2008.06.080","article-title":"A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder","volume":"54","author":"Novara","year":"2008 oct","journal-title":"Eur Urol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.cct.2011.09.019","article-title":"Anticholinergic versus botulinum toxin A comparison trial for the treatment of bothersome urge urinary incontinence: ABC trial","volume":"33","author":"Visco","year":"2012 Janv","journal-title":"Contemp Clin Trials"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"e70004","DOI":"10.1111\/luts.70004","article-title":"Predicting elevated postvoid residual urine volume following onabotulinumtoxinA treatment for overactive bladder: a pilot study","volume":"17","author":"Franco","year":"2025 janv","journal-title":"Low Urin Tract Symptoms"},{"key":"ref56","unstructured":"de Sant\u00e9 Haute Autorit\u00e9. Avis de la Commission de la transparence\u2014BOTOX. [cited 2025 Apr 17]. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/evamed\/CT-17237_BOTOX_HVI_PIS_NE_EPIBoreal_Avis2_modifiele09052019_CT17237.pdf."},{"key":"ref57","first-page":"1","article-title":"Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life","volume":"6","author":"Jayarajan","year":"2013 d\u00e9c 6","journal-title":"Res Rep Urol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1177\/13524585231174580","article-title":"Intravesical injections of botulinum neurotoxin A to treat overactive bladder and\/or detrusor overactivity related to multiple sclerosis: 5-Year continuation rate and specific risk factors for discontinuation\u2014a study from the neuro-urology committee of the French association of urology","volume":"29","author":"Delaval","year":"2023 Juill","journal-title":"Mult Scler"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/nau.25634","article-title":"Patient persistence to onabotulinumtoxinA treatment for overactive bladder using a reduced injection-site paradigm: a retrospective chart review study","volume":"44","author":"Bernstein","year":"2025 f\u00e9vr","journal-title":"Neurourol Urodyn"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"101341","DOI":"10.1016\/j.cont.2024.101341","article-title":"Long term safety, continuation rates and subjective and objective success of posterior tibial nerve stimulation for overactive bladder","volume":"11","author":"Mohamed-Ahmed","year":"2024 sept 1","journal-title":"Continence"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3390\/toxins16080332","article-title":"Efficacy, satisfaction, and compliance: insights from 15 years of botulinum toxin use for female urgency urinary incontinence","volume":"16","author":"Manso","year":"2024 Aug","journal-title":"Toxins"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"33","DOI":"10.15441\/ceem.23.036","article-title":"Overview of clinical study designs","volume":"11","author":"Kim","year":"2024 mars","journal-title":"Clin Exp Emerg Med"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"484","DOI":"10.3390\/toxins16110484","article-title":"Evaluating the efficacy and safety of botulinum toxin in treating overactive bladder in the elderly: a meta-analysis with trial sequential analysis of randomized controlled trials","volume":"16","author":"Chen","year":"2024 nov 8","journal-title":"Toxins"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/SPV.0000000000001256","article-title":"Risk of retention after OnabotulinumtoxinA injection for overactive bladder in a diverse urban population with high BMI and comorbidity rates","volume":"29","author":"Aalami Harandi","year":"2023 janv 1","journal-title":"Urogynecology"},{"key":"ref65","article-title":"MP76-12 overactive bladder patients \u226565 years of age have a similar efficacy and safety profile with onabotulinumtoxina as patients <65 years of age","volume":"191","author":"Moore","year":"2014 avr","journal-title":"J Urology [Internet]"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1002\/nau.70017","article-title":"Variation in the definitions of urinary retention in studies of intravesical botulinum toxin for idiopathic overactive bladder: a narrative systematic review","volume":"44","author":"Stavrou","year":"2025 Apr","journal-title":"Neurourol Urodyn"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/SPV.0000000000001460","article-title":"Variation in defining retention after onabotulinum toxin A for overactive bladder: a systematic review","volume":"30","author":"Castaneda","year":"2024 sept 1","journal-title":"Urogynecology"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/SPV.0000000000001297","article-title":"The correlation of diabetes mellitus and urinary retention from intravesical onabotulinumtoxinA injection for overactive bladder","volume":"29","author":"Takashima","year":"2023 mai 1","journal-title":"Urogynecology"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/iju.12912","article-title":"Impact of onabotulinumtoxinA on quality of life and practical aspects of daily living: a pooled analysis of two randomized controlled trials","volume":"22","author":"Everaert","year":"2015 d\u00e9c","journal-title":"Int J Urol"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/nau.22892","article-title":"Predictive factors of adverse events after intravesical suburothelial onabotulinumtoxina injections for overactive bladder syndrome\u2014a real-life practice of 290 cases in a single center","volume":"36","author":"Jiang","year":"2017 janv","journal-title":"Neurourol Urodyn"},{"key":"ref71","first-page":"1","article-title":"Effectiveness of integrating botulinum toxin type A with rehabilitative strategies for managing spastic diplegia in children: scope review","volume":"8","author":"Donati","year":"2024 oct","journal-title":"OBM Neurobiol"}],"container-title":["Canadian Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.techscience.cn\/files\/cju\/2025\/TSP_CJU-32-3\/TSP_CJU_64912\/TSP_CJU_64912.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T01:38:32Z","timestamp":1763343512000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/CJU\/v32n3\/62621"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":71,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.32604\/cju.2025.064912","relation":{},"ISSN":["1488-5581"],"issn-type":[{"value":"1488-5581","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}